The latest Business updates from the science industry
by Gwyneth Astles
Acquisition Marks Key Step in Global Expansion Strategy
Vantage Nutrition, an ACG Group company, announced on 5th December 2022 that it has acquired Philadelphia-based ‘AquaCap’ - an asset of Nestlé Health Science.
AquaCap is a leading contract manufacturer of liquid-fi lled capsules within the nutritional supplement industry in the United States. Its novel liquid delivery technology allows for the liquid fi lling of hard gelatin and vegetarian capsules.
ACG is the world’s largest integrated supplier of pharmaceutical and nutraceutical products and services. Vantage Nutrition, an ACG group company, already has an excellent reputation as an innovator of two-piece liquid-fi ll capsule solutions. The company’s mission is to be the most effi cient partner in delivering innovative and high-quality nutraceutical products to customers globally.
Karan Singh, Managing Director of ACG, said: “Although ACG has been established in North America for the last 20 years, this marks our first acquisition in the territory and is a key next step in our global expansion strategy. With this increase in our footprint and manufacturing capability, coupled with Vantage’s innovative technologies and 360-degree service offering, we aim to provide the most advanced multiphase liquid-fill solutions for customers across the region.”
Karan Singh, ACG Managing Director. More information online:
ilmt.co/PL/1aMr
Registration now open for Solutions in Science Conference and Exhibition
Registration for the Solutions in Science (SinS) conference and exhibition is now open and early bird rates are available. This meeting brings together experts from a variety of interests and disciplines to discuss the latest developments, challenges and Solutions in science. This event has been organised with special interest groups from the Royal Society of Chemistry the BMSS and ChroSoc. ‘SinS’ will take place in Cardiff from the 4th-6th July and will be of value to scientists from all industries.
The topics of the conference include bioanalytical science for One Health, contaminants of emerging concern, digital solutions, hyphenated techniques and emerging modalities, establishing a sustainable laboratory, green solutions, latest challenges in
molecular characterisation, next generation medicines, non-target analysis and suspect screening, particulate matter in complex samples, and sustainability in the regulated lab.
Attendees will have the opportunity to learn from experts in these fi elds, share their own research and experiences, and network with colleagues from around the world and from different industries. The conference will also feature poster sessions and panel discussions to allow for a more interactive and engaging experience.
If you are interested in staying up-to-date on the latest advancements and innovations in science, this conference is not to be missed. Don’t wait to register, as early bird rates are only available for a limited time. We hope to see you at the Solutions
HUMAN Celebrates its 50th Anniversary
Since its foundation in 1972, HUMAN Gesellschaft für Biochemica und Diagnostica mbH has been developing and marketing comprehensive solutions for in vitro diagnostics (IVD). The portfolio ranges from classical clinical chemistry to innovative molecular diagnostic methods as well as special applications such as assays for autoimmunity testing.
The German medium-sized company has its headquarters in Wiesbaden and its development and production site in Magdeburg. In addition, HUMAN maintains regional sales offi ces in Singapore, China, India, United Arab Emirates, Panama and has local HUMAN representatives in many other countries. With its approximately 300 employees from over
40 nations, its worldwide service and delivery capacities, and a broad network of long-standing sales partners, HUMAN supports medical laboratories in more than 160 countries.
“HUMAN has grown from a small reagent manufacturer to a global player in in vitro diagnostics,” says Dr Björn Breth, CEO of HUMAN since 2019. “For 50 years now, we have been helping to improve healthcare in many places around the world. With our comprehensive portfolio, we cover a wide range of regional needs, from semi-automated devices to fully automated solutions. Through our logistics and services, we are a recognised partner to numerous governmental and non-governmental organisations (NGOs) in support of medical care, particularly in crisis areas. We remain committed to Germany as a business location, where we develop and produce the majority of our products.”
Dr Björn Breth.
At the development and production site in Magdeburg, Germany, scientists work with modern technologies on further developments
and innovations with a focus on clinical chemistry, haematology, haemostasis and immunoassays and in compliance with the highest European quality standards.
Sustainability is a particular concern for HUMAN as a responsible and future-oriented company. A certifi ed environmental management system has been established that meets the requirements of the international ISO 14001 standard and the European EMAS directive. In addition, a resource- effi cient orientation is increasingly taking place in terms of energy generation: at its headquarters, for example, HUMAN already covers over 86% of its annual requirements through renewable energy.
Interesting facts about the 50-year history of HUMAN, milestones and product highlights as well as voices and insights of the cooperation partners can be found on its anniversary page.
More information online:
ilmt.co/PL/2PGJ and
ilmt.co/PL/3Xvk
59541pr@reply-direct.com
in Science conference and look forward to learning from and engaging with you.
More information online:
ilmt.co/PL/e1XX and
ilmt.co/PL/ELl6 59469pr@reply-direct.com
59374pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
